SCHEMBL23978388

SCHEMBL23978388

CC1CC(c2ccc(N)cc2)CCN1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.43
ALDH1A1 P00352 2/20 0.37
HRH3 Q9Y5N1 3/20 0.36
CYP19A1 P11511 1/20 0.36
DRD2 P14416 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
KDM1A O60341 2/20 0.35
MAOA P21397 2/20 0.35
KDM1B Q8NB78 2/20 0.35
RCOR1 Q9UKL0 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27749604 0.82 DRD2 (0.50) SLC18A3DRD2KMT2A
Ammonia Solution, Strong SCHEMBL3406155 0.81 DRD2 (0.49) SLC18A3DRD2KMT2A
SCHEMBL27684536 0.80 HRH3 (0.43) SLC18A3HRH3KCNH2
Hydrochloric Acid SCHEMBL27854009 0.79 DRD2 (0.47) SLC18A3ALDH1A1DRD2
SCHEMBL13470620 0.79 HRH3 (0.56) ALDH1A1HRH3DRD2KCNH2
SCHEMBL23978370 0.78 CYP19A1 (0.40) SLC18A3ALDH1A1CYP19A1KDM4EGAA
Formamide SCHEMBL27459446 0.76 DRD2 (0.42) SLC18A3ALDH1A1HRH3DRD2GAA
SCHEMBL13724169 0.76 SIGMAR1 (0.39) ALDH1A1DRD2MAPTGFER
SCHEMBL158531 0.76 QDPR (0.55) SLC18A3ALDH1A1CYP19A1DRD2HDAC3
SCHEMBL5756822 0.74 SLC6A4 (0.57) HRH3DRD2KDM4EKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
EP-4143191-A2 BICYCLIC KINASE INHIBITORS AND USES THEREOF iOmx Therapeutics AG (DE) 2023-03-08 EP disclosed
WO-2021219731-A2 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-11-04 WO disclosed
WO-2021219731-A2 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF MITF, PRKDC, PRKACA SLC18A3 4530/4885ALDH1A1 3047/4885HRH3 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.